Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis.

Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC.

Biotechnol J. 2019 May 25:e1800563. doi: 10.1002/biot.201800563. [Epub ahead of print]

PMID:
31127682
2.

Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation.

Bandeiras C, Cabral JM, Finkelstein SN, Ferreira FC.

Regen Med. 2018 Dec;13(8):917-933. doi: 10.2217/rme-2018-0034. Epub 2018 Nov 29.

PMID:
30488770
3.

Nosocomial amplification of MERS-coronavirus in South Korea, 2015.

Majumder MS, Brownstein JS, Finkelstein SN, Larson RC, Bourouiba L.

Trans R Soc Trop Med Hyg. 2017 Jun 1;111(6):261-269. doi: 10.1093/trstmh/trx046.

4.

Preventive behaviors and perceptions of influenza vaccination among a university student population.

Hashmi S, D'Ambrosio L, Diamond DV, Jalali MS, Finkelstein SN, Larson RC.

J Public Health (Oxf). 2016 Dec 2;38(4):739-745. doi: 10.1093/pubmed/fdv189. No abstract available.

PMID:
28158761
5.

Medical Students Who Pursue a Joint MD/MBA Degree: Who Are They and Where Are They Heading?

Krupat E, Dienstag JL, Kester WC, Finkelstein SN.

Eval Health Prof. 2017 Jun;40(2):203-218. doi: 10.1177/0163278715620831. Epub 2016 Jan 21.

PMID:
26801747
6.

Fuzzy Modeling to Predict Severely Depressed Left Ventricular Ejection Fraction following Admission to the Intensive Care Unit Using Clinical Physiology.

Pereira RD, Salgado CM, Dejam A, Reti SR, Vieira SM, Sousa JM, Celi LA, Finkelstein SN.

ScientificWorldJournal. 2015;2015:212703. doi: 10.1155/2015/212703. Epub 2015 Aug 5.

7.

Disease-based modeling to predict fluid response in intensive care units.

Fialho AS, Celi LA, Cismondi F, Vieira SM, Reti SR, Sousa JM, Finkelstein SN.

Methods Inf Med. 2013;52(6):494-502. doi: 10.3414/ME12-01-0093. Epub 2013 Aug 28.

8.

Missing data in medical databases: impute, delete or classify?

Cismondi F, Fialho AS, Vieira SM, Reti SR, Sousa JM, Finkelstein SN.

Artif Intell Med. 2013 May;58(1):63-72. doi: 10.1016/j.artmed.2013.01.003. Epub 2013 Feb 19.

PMID:
23428358
9.

Reducing unnecessary lab testing in the ICU with artificial intelligence.

Cismondi F, Celi LA, Fialho AS, Vieira SM, Reti SR, Sousa JM, Finkelstein SN.

Int J Med Inform. 2013 May;82(5):345-58. doi: 10.1016/j.ijmedinf.2012.11.017. Epub 2012 Dec 28.

10.

Vaccine availability in the United States during the 2009 H1N1 outbreak.

Finkelstein SN, Hedberg KJ, Hopkins JA, Hashmi S, Larson RC.

Am J Disaster Med. 2011 Jan-Feb;6(1):23-30.

PMID:
21466026
11.

Trends in the use and role of biomarkers in phase I oncology trials.

Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26. Review.

12.

Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities.

Schachter AD, Ramoni MF, Baio G, Roberts TG Jr, Finkelstein SN.

Value Health. 2007 Sep-Oct;10(5):377-85.

13.

A framework to evaluate the economic impact of pharmacogenomics.

Stallings SC, Huse D, Finkelstein SN, Crown WH, Witt WP, Maguire J, Hiller AJ, Sinskey AJ, Ginsburg GS.

Pharmacogenomics. 2006 Sep;7(6):853-62.

PMID:
16981846
14.

Off-label prescribing among office-based physicians.

Radley DC, Finkelstein SN, Stafford RS.

Arch Intern Med. 2006 May 8;166(9):1021-6.

PMID:
16682577
15.

The economic burden of anemia in cancer patients receiving chemotherapy.

Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, Lee H, Song X, Finkelstein SN.

Value Health. 2005 Mar-Apr;8(2):149-56.

16.

Performance decrements resulting from illness in the workplace: the effect of headaches.

Pransky GS, Berndt E, Finkelstein SN, Verma S, Agrawal A.

J Occup Environ Med. 2005 Jan;47(1):34-40.

PMID:
15643157
17.

Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?

Crown WH, Berndt ER, Baser O, Finkelstein SN, Witt WP, Maguire J, Haver KE.

Front Health Policy Res. 2004;7:95-127.

PMID:
15612337
18.

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW.

JAMA. 2004 Nov 3;292(17):2130-40.

PMID:
15523074
19.

The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.

Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, Sinskey AJ, Wierz D.

Clin Ther. 2004 Aug;26(8):1341-54.

PMID:
15476915
20.

Costs of antidepressant medications associated with inadequate treatment.

Weilburg JB, Stafford RS, O'Leary KM, Meigs JB, Finkelstein SN.

Am J Manag Care. 2004 Jun;10(6):357-65.

Supplemental Content

Loading ...
Support Center